Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

about

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

Item

http://www.wikidata.org/entity/Q57491827

description

scientific article published on 26 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Efficacy and cardiac safety of ...... matic review and meta-analysis

@en

Efficacy and cardiac safety of ...... matic review and meta-analysis

@nl

type

Item

label

Efficacy and cardiac safety of ...... matic review and meta-analysis

@en

Efficacy and cardiac safety of ...... matic review and meta-analysis

@nl

prefLabel

Efficacy and cardiac safety of ...... matic review and meta-analysis

@en

Efficacy and cardiac safety of ...... matic review and meta-analysis

@nl

P1476

Efficacy and cardiac safety of ...... matic review and meta-analysis

@en

P2093

Bilal Arshad

http://www.w3.org/2001/XMLSchema#string

Hong-Yuan Li

http://www.w3.org/2001/XMLSchema#string

Jiu-Song Wu

http://www.w3.org/2001/XMLSchema#string

Kai-Nan Wu

http://www.w3.org/2001/XMLSchema#string

Ke Zhang

http://www.w3.org/2001/XMLSchema#string

Xin Li

http://www.w3.org/2001/XMLSchema#string

Ying-Cun Li

http://www.w3.org/2001/XMLSchema#string

Yu-Tuan Wu

http://www.w3.org/2001/XMLSchema#string

Zhong-Liang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The nuts and bolts of PROSPERO: an international prospective register of systematic reviews

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

Cancer statistics, 2016

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer pa

Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

P304

1789-1797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S176214

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zhou Xu

Ling-Quan Kong

P577

2018-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30310287

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

6165855

http://www.w3.org/2001/XMLSchema#string